Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19064528 | 0.89 | CYP1A2 (0.71) | CYP1A2CYP3A4CYP2D6CYP2C19PTGS2 | |
| SCHEMBL19064549 | 0.88 | CYP1A2 (0.76) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL19088135 | 0.87 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2D6CYP2C19PTGS2 | |
| SCHEMBL1806715 | 0.86 | CYP1A2 (0.70) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL19064543 | 0.83 | CYP1A2 (0.69) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL861655 | 0.81 | PTGS2 (0.69) | CYP1A2CYP3A4CYP2C19PTGS2KDM4E | |
| SCHEMBL16027044 | 0.80 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL19064533 | 0.79 | CYP1A2 (0.78) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E | |
| Hydrochloric Acid SCHEMBL19064529 | 0.79 | CYP1A2 (0.98) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL19064532 | 0.78 | CYP1A2 (0.78) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023315-A1 | METHODS OF ACTIVATING MICROGLIAL CELLS | UNIV NEW YORK STATE RES FOUND (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3397254-B1 | TRYPTAMINE-BASED SHIP INHIBITORS FOR THE TREATMENT OF CANCER | UNIV NEW YORK STATE RES FOUND (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3397254-B1 | TRYPTAMINE-BASED SHIP INHIBITORS FOR THE TREATMENT OF CANCER | UNIV NEW YORK STATE RES FOUND (US) | 2021-10-27 | — | — | EP | disclosed |
| US-10736877-B2 | Tryptamine-based ship inhibitors for the treatment of cancer | SYRACUSE UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-10736877-B2 | Tryptamine-based ship inhibitors for the treatment of cancer | SYRACUSE UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3397254-A1 | TRYPTAMINE-BASED SHIP INHIBITORS FOR THE TREATMENT OF CANCER | The Research Foundation for The State University of New York (US) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017117581-A1 | TRYPTAMINE-BASED SHIP INHIBITORS FOR THE TREATMENT OF CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017117581-A1 | TRYPTAMINE-BASED SHIP INHIBITORS FOR THE TREATMENT OF CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170189380-A1 | TRYPTAMINE-BASED SHIP INHIBITORS FOR THE TREATMENT OF CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-07-06 | — | — | US | disclosed |
| US-20170189380-A1 | TRYPTAMINE-BASED SHIP INHIBITORS FOR THE TREATMENT OF CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-07-06 | — | — | US | disclosed |
| US-20170189380-A1 | TRYPTAMINE-BASED SHIP INHIBITORS FOR THE TREATMENT OF CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189380-A1 | TRYPTAMINE-BASED SHIP INHIBITORS FOR THE TREATMENT OF CANCER | TPH1, INPP5B, INPP5D | CYP1A2 4798/4885CYP3A4 4809/4885CYP2D6 4488/4885 |
| US-10736877-B2 | Tryptamine-based ship inhibitors for the treatment of cancer | TPH1, INPP5B, INPP5D | CYP1A2 4798/4885CYP3A4 4809/4885CYP2D6 4488/4885 |
| US-20220023315-A1 | METHODS OF ACTIVATING MICROGLIAL CELLS | LPCAT3, PLAAT2, PLA2G4B | CYP1A2 4877/4885CYP3A4 4884/4885CYP2D6 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.